Emerging studies suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may represent a significant development for body management . Preliminary patient tests have shown impressive reductions in abdominal mass , possibly surpassing current obesity treatments. However , further assessment is